0001725160-21-000200.txt : 20211004
0001725160-21-000200.hdr.sgml : 20211004
20211004211657
ACCESSION NUMBER: 0001725160-21-000200
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211001
FILED AS OF DATE: 20211004
DATE AS OF CHANGE: 20211004
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bunker Kevin D.
CENTRAL INDEX KEY: 0001807484
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39263
FILM NUMBER: 211304958
MAIL ADDRESS:
STREET 1: C/O ZENTALIS PHARMACEUTICALS, INC.
STREET 2: 530 SEVENTH AVENUE, SUITE 2201
CITY: NEW YORK
STATE: NY
ZIP: 10018
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Zentalis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001725160
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 530 SEVENTH AVENUE, SUITE 2201
CITY: NEW YORK
STATE: NY
ZIP: 10018
BUSINESS PHONE: (212) 433-3791
MAIL ADDRESS:
STREET 1: 530 SEVENTH AVENUE, SUITE 2201
CITY: NEW YORK
STATE: NY
ZIP: 10018
FORMER COMPANY:
FORMER CONFORMED NAME: Zentalis Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20200107
FORMER COMPANY:
FORMER CONFORMED NAME: Zeno Pharma, LLC
DATE OF NAME CHANGE: 20171212
4
1
wf-form4_163339659793245.xml
FORM 4
X0306
4
2021-10-01
0
0001725160
Zentalis Pharmaceuticals, Inc.
ZNTL
0001807484
Bunker Kevin D.
C/O ZENTALIS PHARMACEUTICALS, INC.
530 SEVENTH AVENUE, SUITE 2201
NEW YORK
NY
10018
0
1
0
0
Chief Operating Officer
Common Stock
2021-09-24
5
G
0
E
350
0
D
995067
D
Common Stock
2021-09-24
5
G
0
E
350
0
A
350
I
As UTMA custodian for sons
Common Stock
2021-10-01
4
S
0
1416
64.7309
D
7004
I
See Footnote
Common Stock
2021-10-01
4
S
0
3121
65.8002
D
3883
I
See Footnote
Common Stock
2021-10-01
4
S
0
3679
66.8865
D
204
I
See Footnote
Common Stock
2021-10-01
4
S
0
204
67.4449
D
0
I
See Footnote
Transfer to Reporting Person in his capacity as custodian for sons under Uniform Transfers to Minors Act. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any.
Includes 576 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on September 30, 2021.
The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $64.26 to $65.21. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $65.29 to $66.27. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $66.41 to $67.34. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $67.44 to $67.45. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
By: /s/ Melissa B. Epperly, Attorney-in-Fact for Kevin D. Bunker
2021-10-04